AlphAIAlphAI — Financial news for AI agents
investing.com$HBIO

Harvard Bioscience earnings beat by $0.21, revenue topped estimates

Harvard Bioscience (HBIO) reported Q3 EPS of -$0.06, beating estimates by $0.21, with revenue of $22.2M, exceeding expectations. The stock is up 36.59% in 3 months and 49.63% in 12 months, with a 'fair performance' financial health score according to InvestingPro.

Original reporting
investing.com
Published Nov 10, 2026, 12:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$HBIO
Bullish
medium confidence
Mentioned
$HBIO
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HBIOBullishMed
01

Why it matters

Earnings beat may attract short‑term traders, but the company’s ongoing losses keep risk elevated.

02

Market read

Primary earnings disclosure for a micro‑cap; modest trading relevance.

03

What to watch

Potential upcoming product launches or contract wins not disclosed could further influence the stock.

Relevance 6/10Novelty 7/10Timing: post‑market today

Background

Harvard Bioscience (NASDAQ:HBIO) is a small‑cap provider of life‑science research tools. The company has been volatile, with a 36% 3‑month price gain.

Company-level read

Ticker impact

$HBIOBullishMedium confidence
Context

Harvard Bioscience reported Q3 EPS of -$0.060, beating estimates by $0.21 and revenue of $22.2M versus $21.85M consensus.

Expected impact

likely upward pressure as the market prices in the earnings beat

Evidence & confidence

The beat is modest in absolute dollars but represents a material improvement over expectations for a micro‑cap, prompting short‑term buying.

Market effects

Sector

May provide a modest boost to the life‑science equipment sector as a peer shows earnings resilience.

Regional

Limited to U.S. micro‑cap investors; no broader regional effect.

Global

Low; the company is small and not a market driver.

Counterpoint

What could challenge this read

The beat is small and the company remains loss‑making; the rally could be short‑lived.

Key entities

  • company
    Harvard Bioscience

    Life‑science research equipment manufacturer.

Read at source← All news

Related articles

Med

Harvard Bioscience, Inc. Q3 2026 Earnings Call Summary

Harvard Bioscience reported Q3 2026 revenue growth of 8%, driven by CRO demand and new product innovations. China revenue rose 31% year-over-year. Gross margins were pressured by lower-margin products. Full-year revenue guidance was reaffirmed at 3-5% growth, but adjusted EBITDA guidance was lowered. Project Viking is expected to deliver cost savings in 2027. Management expects to launch a bioproduction version of electroporation technology in mid-2027.

finance.yahoo.com
$HBIOHigh

Harvard Bioscience (HBIO) Q3 2026 Earnings Call Transcript

Harvard Bioscience (HBIO) reported Q3 2026 revenue of $22.2M, up 8% YoY, driven by CRO and distribution partner demand. Adjusted EBITDA was $1.8M, impacted by lower-margin products. The company reaffirmed full-year revenue guidance of 3-5% growth and adjusted gross margin target of 57-59%. Project Viking, a manufacturing consolidation plan, is on track for 2027 completion, expected to generate $3M in cost savings.

finance.yahoo.com
$HBIOMed

Harvard Bioscience Announces Third Quarter 2026 Financial Results

HARVARD BIOSCIENCE INC (HBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2026 Financial Results · Third Quarter 2026 Revenue Growth of 8% Year Over Year to $22.2 Million · Reaffirms Full Year 2026 Revenue Guidance of 3%-5% Year Over Year Growth HOLLISTON, Mass., November 10, 2026 (GLOBE NEWSWIRE)

SEC EDGAR 8-K
$HBIOMedAI 8/10

Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript

Harvard Bioscience (HBIO) reported Q2 2026 revenue of $22.7M, up 11%, and adjusted EBITDA of $1.7M, up 11%. Full-year revenue guidance was raised to 3-5% growth, but gross margin guidance was lowered to 57-59% due to product and geographic mix shifts. The company expects $3M in cost savings from Project Viking in 2027. Americas and APAC regions showed strong growth, while Europe grew modestly. Adjusted EPS was -$0.14, and Q3 revenue guidance is $21.0M-$22.6M.

fool.com
$HBIOMed

Harvard Bioscience, Inc. Q2 2026 Earnings Call Summary

Harvard Bioscience (HBIO) reported Q2 2026 revenue up 11%, driven by CRO demand and double-digit growth in telemetry and CMT portfolios. China sales rose on its “Made in China” BTX line. Recurring revenue reached 55%. Full-year guidance raised to 3% to 5% growth, but adjusted gross margin cut 100 bps to 57% to 59%, with Project Viking cost savings.

yahoo.com